Schnyder Boucard, | |
1755 Highway 34 E, Newnan, GA 30265-5631 | |
(770) 502-2175 | |
Not Available |
Full Name | Schnyder Boucard |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Location | 1755 Highway 34 E, Newnan, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831800317 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | 11312 (Georgia) | Secondary |
363A00000X | Physician Assistant | 11312 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Schnyder Boucard, 1755 Highway 34 E, Newnan, GA 30265-5631 Ph: (770) 502-2175 | Schnyder Boucard, 1755 Highway 34 E, Newnan, GA 30265-5631 Ph: (770) 502-2175 |
News Archive
Merge Healthcare Incorporated and AMICAS, Inc. today announced that the tender offer by Project Ready Corp., a wholly-owned subsidiary of Merge Healthcare, for all of the outstanding shares of AMICAS common stock has been extended to 5:00 p.m., New York City, New York time, on Friday, April 23, 2010, unless further extended.
Recently, it has been demonstrated that Transcatheter arterial chemoembolization (TACE) improves survival compared with best supportive care in meta-analyses of randomized trials and in two individual clinical trials.
A public and scientific discussion is currently taking place focusing on the question whether substances at low concentrations may lead to health impairments in humans. For this reason, an increasing number of experimental studies to test such effects are currently conducted using different chemicals.
Constantine Frantzides M.D., Ph.D., F.A.C.S., Director of the Chicago Institute of Minimally Invasive Surgery, staff surgeon and Director of the Laparoscopic Fellowship Program at Saint Francis Hospital, has pioneered a new minimally-invasive surgical technique for the treatment of Barrett's esophagus and high-grade dysplasia.
iRhythm Technologies, Inc., a healthcare information services company, today announced that it closed a $17 million Series E financing led by Novo A/S, a global life science investment firm.
› Verified 6 days ago